Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -127,111 | -59,793 | -356,422 | -210,470 | -125,777 |
| Depreciation Amortization | 7,987 | 5,385 | 108,639 | 21,742 | 12,805 |
| Accounts receivable | -5,704 | -4,034 | -7,990 | -8,384 | -2,242 |
| Accounts payable and accrued liabilities | 3,703 | 5,095 | -5,448 | -9,711 | 1,975 |
| Other Working Capital | -32,937 | -28,489 | 665 | -17,516 | -16,444 |
| Other Operating Activity | 31,180 | 12,336 | 67,008 | 60,973 | 24,188 |
| Operating Cash Flow | $-122,882 | $-69,500 | $-193,548 | $-163,366 | $-105,495 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -604 | -870 | -3,210 | -1,922 | -920 |
| Purchase Of Investment | -128,859 | -29,294 | -347,966 | -321,199 | -163,676 |
| Sale Of Investment | 185,247 | 125,480 | 232,178 | 161,183 | 113,183 |
| Other Investing Activity | 0 | 0 | -19,800 | -17,820 | -9,900 |
| Investing Cash Flow | $55,784 | $95,316 | $-138,798 | $-179,758 | $-61,313 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 98,150 | 98,150 | 98,150 |
| Debt Repayment | -8,899 | -2,486 | -11,097 | -5,000 | -1,760 |
| Common Stock Issued | 114,153 | 9,481 | 252,834 | 250,653 | 33,941 |
| Other Financing Activity | -4,518 | -3,730 | -8,193 | -5,936 | -3,853 |
| Financing Cash Flow | $100,736 | $3,265 | $331,694 | $337,867 | $126,478 |
| Beginning Cash Position | 115,017 | 115,017 | 115,669 | 115,669 | 115,669 |
| End Cash Position | 148,655 | 144,098 | 115,017 | 110,412 | 75,339 |
| Net Cash Flow | $33,638 | $29,081 | $-652 | $-5,257 | $-40,330 |
| Free Cash Flow | |||||
| Operating Cash Flow | -122,882 | -69,500 | -193,548 | -163,366 | -105,495 |
| Capital Expenditure | -604 | -870 | -3,210 | -1,922 | -920 |
| Free Cash Flow | -123,486 | -70,370 | -196,758 | -165,288 | -106,415 |